Literature DB >> 17108042

Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.

Devin B Lowe1, Michael H Shearer, Cynthia A Jumper, Robert K Bright, Ronald C Kennedy.   

Abstract

Simian virus 40 (SV40) large tumor antigen (Tag) represents a virus-encoded tumor-specific antigen expressed in many types of human cancers and a potential immunologic target for antitumor responses. Fc receptors are important mediators in the regulation and execution of host effector mechanisms against conditions including infectious diseases, autoimmunity, and cancer. By examining tumor protection in SV40 Tag-immunized wild-type BALB/c mice using an experimental pulmonary metastasis model, we attempted to address whether engagement of the immunoglobulin G Fc receptors (FcgammaRs) on effector cells is necessary to mediate antitumor responses. All immunized BALB/c FcgammaR-/- knockout mice developed anti-SV40 Tag antibody responses prior to experimental challenge with a tumorigenic cell line expressing SV40 Tag. However, all mice deficient in the activating FcgammaRI (CD64) and FcgammaRIII (CD16) were unable to mount protective immunologic responses against tumor challenge and developed tumor lung foci. In contrast, mice lacking the inhibitory receptor FcgammaRII (CD32) demonstrated resistance to tumorigenesis. These results underscore the importance of effector cell populations expressing FcgammaRI/III within this murine tumor model system, and along with the production of a specific humoral immune response, antibody-dependent cell-mediated cytotoxicity (ADCC) may be a functioning mechanism of tumor clearance. Additionally, these data demonstrate the potential utility of ADCC as a viable approach for targeting vaccination strategies that promote FcgammaRI/III scavenging pathways against cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108042      PMCID: PMC1797535          DOI: 10.1128/JVI.01943-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  DNA vaccines expressing antigens with a stress protein-capturing domain display enhanced immunogenicity.

Authors:  Jörg Reimann; Reinhold Schirmbeck
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

2.  Transplantable mouse tumor line induced by injection of SV40-transformed mouse kidney cells.

Authors:  S Kit; T Kurimura; D R Dubbs
Journal:  Int J Cancer       Date:  1969-07-15       Impact factor: 7.396

3.  Expression of simian virus 40 T antigen in insect cells using a baculovirus expression vector.

Authors:  R E Lanford
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

4.  CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.

Authors:  Ronald C Kennedy; Michael H Shearer; Allison M Watts; Robert K Bright
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

5.  Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.

Authors:  Meili Zhang; Zhuo Zhang; Kayhan Garmestani; Carolyn K Goldman; Jeffrey V Ravetch; Martin W Brechbiel; Jorge A Carrasquillo; Thomas A Waldmann
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

6.  Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

Authors:  Francisco J Hernandez-Ilizaliturri; Venkata Jupudy; Julie Ostberg; Ezogelin Oflazoglu; Amy Huberman; Elizabeth Repasky; Myron S Czuczman
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

Review 7.  A role for antibodies in tumor immunity.

Authors:  Ronald C Kennedy; Michael H Shearer
Journal:  Int Rev Immunol       Date:  2003 Mar-Apr       Impact factor: 5.311

8.  Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

Authors:  Sébastien Dall'Ozzo; Sophie Tartas; Gilles Paintaud; Guillaume Cartron; Philippe Colombat; Pierre Bardos; Hervé Watier; Gilles Thibault
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

9.  Differential regulation of murine B cell Fc gamma RII expression by CD4+ T helper subsets.

Authors:  C M Snapper; J J Hooley; U Atasoy; F D Finkelman; W E Paul
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

10.  The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors:  Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more
  8 in total

1.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

2.  CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.

Authors:  Joel F Aldrich; Devin B Lowe; Michael H Shearer; Richard E Winn; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

3.  Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen.

Authors:  Devin B Lowe; Michael H Shearer; Joel F Aldrich; Richard E Winn; Cynthia A Jumper; Ronald C Kennedy
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

4.  HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.

Authors:  Ilaria Grazia Zizzari; Filippo Veglia; Federica Taurino; Hassan Rahimi; Elena Quaglino; Francesca Belleudi; Federica Riccardo; Morena Antonilli; Chiara Napoletano; Filippo Bellati; Pierluigi Benedetti-Panici; Maria Rosaria Torrisi; Luigi Frati; Marianna Nuti; Aurelia Rughetti
Journal:  J Mol Med (Berl)       Date:  2011-08-16       Impact factor: 4.599

5.  Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.

Authors:  Branka Petricevic; Johannes Laengle; Josef Singer; Monika Sachet; Judit Fazekas; Guenther Steger; Rupert Bartsch; Erika Jensen-Jarolim; Michael Bergmann
Journal:  J Transl Med       Date:  2013-12-12       Impact factor: 5.531

Review 6.  IgE-based immunotherapy of cancer: challenges and chances.

Authors:  J Singer; E Jensen-Jarolim
Journal:  Allergy       Date:  2013-10-14       Impact factor: 13.146

7.  Immunotoxicity of zinc oxide nanoparticles with different size and electrostatic charge.

Authors:  Cheol-Su Kim; Hai-Duong Nguyen; Rosa Mistica Ignacio; Jae-Hyun Kim; Hyeon-Cheol Cho; Eun Ho Maeng; Yu-Ri Kim; Meyoung-Kon Kim; Bae-Keun Park; Soo-Ki Kim
Journal:  Int J Nanomedicine       Date:  2014-12-15

8.  Highly individual patterns of virus-immune IgG effector responses in humans.

Authors:  Eugenia Corrales-Aguilar; Mirko Trilling; Henrike Reinhard; Valeria Falcone; Albert Zimmermann; Ortwin Adams; Sabine Santibanez; Hartmut Hengel
Journal:  Med Microbiol Immunol       Date:  2016-05-18       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.